Similar articles for PMID: 31698414

Year	Number of Results
1998	1
2002	1
2003	1
2004	1
2005	1
2006	2
2007	4
2008	5
2009	6
2010	5
2011	2
2012	2
2013	4
2014	6
2015	4
2016	18
2017	19
2018	12
2019	9
2020	4
2021	2
2022	1
2024	0

1

PET-adapted treatment of Hodgkin lymphoma.

Hutchings M. Hutchings M. Blood. 2019 Oct 10;134(15):1200-1201. doi: 10.1182/blood.2019002420. Blood. 2019. PMID: 31698414 Free article. No abstract available.

2

FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?

Hutchings M. Hutchings M. Hematol Oncol Clin North Am. 2014 Feb;28(1):87-103. doi: 10.1016/j.hoc.2013.10.008. Hematol Oncol Clin North Am. 2014. PMID: 24287070 Review.

3

Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.

Bair SM, Svoboda J. Bair SM, et al. PET Clin. 2019 Jul;14(3):353-368. doi: 10.1016/j.cpet.2019.03.008. Epub 2019 Apr 12. PET Clin. 2019. PMID: 31084775 Review.

4

[FDG-PET in Hodgkin lymphoma].

Kobe C, Dietlein M, Mauz-Körholz C, Engert A, Borchmann P, Sabri O, Schober O, Schicha H, Kluge R. Kobe C, et al. Nuklearmedizin. 2008;47(6):235-8; quiz N75-6. doi: 10.3413/nukmed-0216. Nuklearmedizin. 2008. PMID: 19057796 German.

5

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Sickinger MT, et al. Cochrane Database Syst Rev. 2015 Jan 9;1:CD010533. doi: 10.1002/14651858.CD010533.pub2. Cochrane Database Syst Rev. 2015. PMID: 25572491 Review.

6

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?

Adams HJA, Kwee TC. Adams HJA, et al. Br J Haematol. 2018 Apr;181(1):122-123. doi: 10.1111/bjh.14495. Epub 2016 Dec 26. Br J Haematol. 2018. PMID: 28025838 Free article. No abstract available.

7

Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma.

Adams HJA, Kwee TC. Adams HJA, et al. J Clin Oncol. 2017 Aug 20;35(24):2850-2851. doi: 10.1200/JCO.2017.73.3816. Epub 2017 Jul 6. J Clin Oncol. 2017. PMID: 28682684 No abstract available.

8

Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma.

Adams HJA, Kwee TC; NCCN Guidelines Staff. Adams HJA, et al. J Natl Compr Canc Netw. 2018 Mar;16(3):226-228. doi: 10.6004/jnccn.2018.7011. J Natl Compr Canc Netw. 2018. PMID: 29523660 No abstract available.

9

18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.

Giraudo C, Raderer M, Karanikas G, Weber M, Kiesewetter B, Dolak W, Simonitsch-Klupp I, Mayerhoefer ME. Giraudo C, et al. Invest Radiol. 2016 Mar;51(3):163-9. doi: 10.1097/RLI.0000000000000218. Invest Radiol. 2016. PMID: 26784400 Free PMC article.

10

Only a Small Proportion of Patients With Early-Stage Hodgkin Lymphoma May Potentially Benefit From Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment Escalation.

Adams HJA, Kwee TC. Adams HJA, et al. J Clin Oncol. 2019 Dec 1;37(34):3323. doi: 10.1200/JCO.19.01491. Epub 2019 Sep 30. J Clin Oncol. 2019. PMID: 31566991 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

90 results

Results by year